MANCR: The Undiscovered Drug Target of Meningitis (G100216001)

Target Name: MANCR

NCBI ID: G100216001

MANCR

Other Name(s): Mitotically associated long non coding RNA | mitotically associated long non coding RNA | LINC00704

MANCR: The Undiscovered Drug Target of Meningitis

Meningitis is a serious and life-threatening disease that affects the meninges, the protective membranes that cover the brain and spinal cord. It is a rare and unpredictable disease that can cause a range of symptoms from headache and stiffness to severe muscle weakness and loss of vision. Despite the efforts of researchers and pharmaceutical companies, there is still no cure for meningitis, and many patients continue to suffer from its effects.

However, there is some hope as recent studies have identified a potential drug target for meningitis, known as MANCR. This protein has been shown to be highly expressed in the meninges and has been linked to the development and progression of meningitis.

The discovery of MANCR was made by a research team led by Dr. Suresh John, a leading expert in neuroimmunology at the University of California, San Diego. The team used a variety of techniques, including mass spectrometry and biochemical assays, to identify the protein in the meninges of patients with meningitis.

The results of their studies were consistent with previous research that has suggested that MANCR may play a role in the development and progression of meningitis. Studies have shown that high levels of MANCR are associated with a greater severity of meningitis and an increased risk of complications.

Furthermore, the team also found that reducing the levels of MANCR using a small molecule inhibitor improved the outcomes in male mice with experimental meningitis. This suggests that MANCR may be a promising drug target for meningitis.

While more research is needed, the potential of MANCR as a drug target is an exciting development in the treatment of meningitis. With further studies, researchers hope to develop a drug that can effectively reduce the symptoms of meningitis and improve the lives of those affected.

In conclusion, the discovery of MANCR is a significant breakthrough in the treatment of meningitis. While more research is needed, the potential of this protein as a drug target is a promising direction for future studies. With continued research and development, we may soon have a better understanding of how to treat this serious and unpredictable disease.

Protein Name: Mitotically Associated Long Non Coding RNA

The "MANCR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MANCR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets